)
Inhibrx Biosciences (INBX) investor relations material
Inhibrx Biosciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was $2.0M; net loss was $38.7M, or $2.46 per share, and cash and cash equivalents totaled $199.5M at September 30, 2026.
Clinical progress included positive Phase 3 chondrosarcoma results, encouraging ordastobart HNSCC Phase 2 data, and FDA review of the ozekibart BLA.
Financial highlights
Q3 revenue was $2.0M from a Pfizer license fee versus none in Q3 2025; 9M revenue was $2.0M versus $1.3M in 2025, reflecting Pfizer and Scithera license fees, respectively.
Q3 R&D expense fell 9% YoY to $26.0M from $28.5M; G&A rose 47% to $7.8M from $5.3M, primarily due to pre-commercialization and personnel costs.
9M R&D expense declined 14% to $75.1M; G&A increased 23% to $21.7M, driven primarily by pre-commercialization and personnel expenses.
Q3 net loss was $38.7M versus $35.3M YoY; 9M net loss was $108.8M versus $107.2M.
Q3 operating loss was $31.7M versus $33.8M; 9M interest expense was $18.0M versus $9.0M, reflecting higher debt balances and non-cash debt costs.
Outlook and guidance
Cash and cash equivalents are expected to fund operations for at least 12 months from the November 2026 filing; substantial additional capital will be needed for future development and commercialization.
R&D expenses are expected to rise as clinical programs advance, particularly in later-stage trials; pre-commercialization and potential launch costs are also expected to increase.
Interim results from two additional CRC cohorts are expected in Q1 2027; initial readouts for expanded HPV-positive OPSCC and perioperative NSCLC studies are targeted for mid-2027.
Updated Phase 1/2 Ewing sarcoma results were planned for CTOS on Nov. 19–20, 2026; chondrosarcoma commercial readiness and BLA-supporting manufacturing activities are progressing alongside regulatory review.
- INBRX-106 plus pembrolizumab delivers superior efficacy and tolerability in HNSCC, especially for HPV+ patients.INBX
Study update - Q2 net loss reached $36.7M as cash rose to $219.5M and key clinical milestones approach.INBX
Q2 2026 - Biotech registers 2.45M shares for resale, advancing oncology pipeline with $255M cash.INBX
Registration filing - Board elections, auditor ratification, and robust governance practices headline the annual meeting.INBX
Proxy filing - $2.0B gain from Sanofi deal drove Q2 net income to $1.86B; cash reserves at $226.9M.INBX
Q2 2024 - $2.0B merger gain drove $1.74B net income, with strong cash reserves and no debt outstanding.INBX
Q3 2024 - Virtual meeting to elect directors and ratify auditor, with board support for both proposals.INBX
Proxy filing - Net loss narrowed to $43.3M in Q1 2025, with strong cash reserves and lower R&D spend.INBX
Q1 2025 - Shareholders will vote on director elections and auditor ratification, with strong governance in place.INBX
Proxy filing
)
)
)
)
)
)
)
)